(图片来源:国际中子俘获疗法大会网站)
前言
2026 年 10 月 30 日,阿根廷布宜诺斯艾利斯。
第 21 届国际中子俘获治疗大会(ICNCT-21)闭幕式上,一个消息从南半球传回中国——
下一届 ICNCT,2028 年,中国。
中国科学院院士陈和生出任下一届大会主席。
阿根廷·布宜诺斯艾利斯
第 21 届国际中子俘获治疗大会合影
PART.01
BNCT 是什么?对肿瘤患者意味着什么?
示意图
如果你是第一次听到"硼中子俘获治疗"(BNCT),可以把它理解成一种"靶向爆破"式的放疗。
两步走:
? 第一步:
给患者注射一种含硼药物(如硼[1?B]苯丙氨酸(boronophenylalanine,简称 BPA)。这种药物有个特点:它会选择性地聚集在肿瘤细胞里,正常组织里很少。
? 第二步:
用低能超热中子束照射肿瘤部位。硼-10 原子核捕获一个中子后,发生裂变,释放出两个短程粒子(α 粒子和锂-7 粒子),这两个粒子的射程只有约一个细胞直径。
T/N (肿瘤组织与正常组织的硼浓度比值)比越高,说明药物在肿瘤里富集越多、在正常组织里残留越少 —— 中子照射时,肿瘤受到的杀伤远大于周围健康组织,治疗就越安全、越有效。它是评估硼药 BNCT 适用性的核心指标之一。
这和传统放疗有什么不同?
传统放疗(X 射线、质子束)像"地毯式轰炸"——射线穿过的路径上,正常组织和肿瘤一起受伤。BNCT 像"精确制导"——药物自己找到肿瘤,中子束只是"引爆开关"。
它的优势:
? 器官与功能保留:
对于罹患骨肉瘤的青少年患者,BNCT 意味着保留肢体、保留未来独立生活的能力;对于乳腺癌患者,意味着保留乳房、保留尊严;对于前列腺癌患者,意味着避免根治术及其高发的尿失禁风险。这不是简单的"少切一点",而是改变一个人后半生的生活轨迹。
? 复发末线患者的新希望:
对于经过多轮手术、放疗、化疗后仍然复发的患者,传统治疗往往已经无路可走。BNCT 不受正常组织累积剂量的限制,是黑暗中的一束光——当所有其他治疗都用完了,这可能是由死向生的希望。
? 疗程短、设备投入低:
质子治疗通常需要约 30 次照射,重离子治疗约 12–16 次,而 BNCT 通常只需 1–2 次照射即可完成治疗,患者门诊即可完成。与质子、重离子设备相比,BNCT 加速器的建设投入和运行费用更低,更便于在不同国家快速部署推广。
目前,BNCT 主要用于局部复发、无法再次手术或再次放疗的头颈部肿瘤---由于疗法新,获批的适应症要用于局部复发、无法再次手术或再次放疗的头颈部肿瘤,后续有望向其它实体瘤拓展。
PART.02
本届大会:学术界与产业界的最新动态
第 21 届国际中子俘获治疗大会现场图
ICNCT 是 BNCT 领域历史最久、规格最高的国际学术会议,每两年一届,从 1968 年办到现在,这个领域从反应堆迈向加速器时代,从日本一家走向全球多点。本届大会,又传递了哪些新信号?
学术界——五个前沿方向的最新进展:
1.新型硼载体与递送体系:除成熟 BPA 外,PBC-IP、白蛋白偶联硼分子、BODIPY 诊疗一体化硼探针、对流增强递送(CED,绕过血脑屏障)等新一代方案成为热门,重点攻克胶质母细胞瘤等脑肿瘤中传统 BPA 入脑不足的难题。
2. 放射生物学与免疫效应:BNCT 诱导的免疫原性细胞死亡、细胞外囊泡标志物等方向持续产出新数据,为 BNCT 联合免疫治疗提供了理论基础;口腔黏膜防护策略也在持续优化。
3. 剂量学与生物等效换算:不同射线、不同模型下 BNCT 生物等效剂量换算尚无全球统一标准,B-NIT 等新概念持续被研讨。
4. 临床队列与适应症拓展:大阪公布了 285 例头颈肿瘤长期随访数据;儿童脑肿瘤、黑色素瘤 BNCT 病例数据陆续公布;胶质母细胞瘤手术切除程度与 BNCT 预后的相关性研究,为 BNCT 作为术后挽救治疗提供了更多临床证据。
5.硼成像与体内硼定量:由于1?F-FBPA PET 在活体评估 BPA 肿瘤摄取时,受氟-18 半衰期(约 110 分钟)限制,必须就近配套回旋加速器,这给诊断和治疗带来不便,因此,固态核径迹探测(SSNTD)和 LA-ICP-MS 等定量方法也在快速发展。
第 21 届国际中子俘获治疗大会学术会议现场图
产业界——全球设备部署正在加速:
?日本:关西 BNCT 中心累计照射已超 600 例,大阪队列 285 例长期随访,临床数据全球最深厚。
?欧洲:芬兰赫尔辛基大学医院 2025 年启动欧洲首个院内加速器 BNCT 临床,意大利、西班牙多点跟进。
?美国:威斯康星大学麦迪逊分校进入筹建阶段,多家加速器公司获得融资。
?韩国:加速器 BNCT 项目在推进。
?中国:已有多条加速器 BNCT 系统进入临床试验或注册申报阶段,覆盖华东、华南多家医院端开展临床探索。
一个共识正在形成:BNCT 已经从"日本一家的故事",变成了全球多点开花的赛道—— 而中国,正在从跟跑者变成下一个 C 位。
第 21 届国际中子俘获治疗大会交流活动现场图
PART.03
中国凭什么?
下一届放在中国,不是偶然。过去几年,中国的 BNCT 正在全链条快速追赶 —— 从加速器设备到硼药研发,从临床布局到学术产出,不再只是单点跟进:
国科中子:
依托于中科院高能物理研究所(东莞松山湖),中国散裂中子源——央视称它为探索微观世界的"超级显微镜"——建成了国产首台拥有完全自主知识产权的加速器 BNCT 系统,首装东莞人民医院,2.78 MeV 射频四极加速器,旋转锂靶,超热中子通量 ≥1.02×10? n/s/cm2。2024 年可用率超过 95%。
普利制药:
与国科中子联合申报的硼药BPA,由东莞人民医院肿瘤中心主任刘志刚团队开展临床研究: I 期临床完成 21 例复发头颈癌,安全性得到验证,客观缓解率远超传统化疗或免疫治疗的现有水平。Ⅱ期临床试验正在推进中。
中硼医疗:
首装厦门弘爱医院,已完成复发头颈癌 I 期临床、启动 II 期,2024 年 11 月起系统可用率超过 99%。自主研发 NeuMANTA/COMPASS 治疗计划系统。
华硼中子:
以"锂靶 + BSA"紧凑加速器为核心,配套自产硼法仑,形成"装备 + 药物"闭环。超热中子通量 1.2×10? n/cm2/s,质子能量 2.8 MeV,束流 ≥30 mA,治疗深度 ≤11 cm,符合 IEC 60601-2-93 标准。2026 年 3 月获 NMPA 临床试验批准(IND),已进入 I 期。
凤麟核:
以 TopMC 蒙特卡洛引擎为核心,打造中国首个专用中子治疗计划系统 N-TPS,剂量引擎偏差 <3%(优于 IAEA 7% 的建议标准),AI 辅助计划 10 秒内完成。在重庆、青岛、南京、安庆、合肥布局五大基地,覆盖光子/电子、质子、BNCT 全谱系放疗装备。
此外,山东、浙江、四川等地均有 BNCT 中心在建或已签约;海南博鳌乐城国际医疗旅游先行区已落地引进日本 BNCT 项目。截至目前,中国已有4 家中心进入临床试验阶段,3 家安装调试中,7 家在建或已签约。
设备端的爆发,已经是既成事实。
设备之外,中国的学术研究也在多点突破。
南京大学在本届大会报告了物理约束的机器学习算法,用于加速器 BNCT 在线中子谱实时重建。北京大学刘志博团队在新型硼药小分子设计方向持续产出,在 Angew. Chem. 发表双硼氨基酸分子,兼具 PET 成像与 BNCT 治疗潜力。浙江大学医学院附属第二医院在硼递送剂开发、微剂量学和治疗计划优化方面开展系统研究。南京航空航天大学核技术与多学科交叉创新中心与意大利国家核物理研究院(INFN)、帕维亚大学长期合作加速器 BNCT 关键技术,成果入选江苏省国际产学研用十大合作成果。
PART.04
但有设备,就够了吗?
不够。
BNCT 是一种药械组合疗法——中子束是"枪",硼药是"子弹"。没有药,再先进的加速器也只是一台空转的机器,无法真正触达患者,无法真正治疗一个病人。
硼药决定了三件事:
1. 能治多少患者:药物在肿瘤里的浓度越高、T/N越高,能覆盖的患者群体就越大。
2. 能治什么癌:不同的硼药靶向不同的肿瘤类型——BPA 针对头颈癌,新型硼药可以扩展到乳腺癌、骨肉瘤、胰腺癌、脑肿瘤。
3. 治疗可及性:药物能否在当地获批、能否稳定 GMP 供应、价格是否可承受,直接决定了一台设备能不能真正服务患者。
硼药所能抵达的边界,定义了 BNCT 疗法的临床边界。
全球目前只有一种 BNCT 药物获批上市——日本 Stella Pharma 的 borofalan(Steboronine),仅在日本国内使用。每一台新设备投入临床,都需要一个在当地获准使用、能稳定供应的硼药。
这也是为什么,当全球 BNCT 设备正在加速部署的时候,硼药这一端,正在成为整个行业最关键的一环。
PART.05
在这个领域,普利做了什么?
首个硼药,BPA——已跑通从原料到临床的全链条
1?B-BPA: Ⅱ 期临床推进中。 化学纯度 99.9%,硼-10 丰度 99%,从原料到配方,到成品制造全部自产。原料药已向美国 FDA 递交 II 型药物主文件(DMF),并已完成 FDA Pre-IND 沟通;在中国已完成 I 期临床试验,Ⅱ期临床试验正在推进中。可供研究级和 GMP 级原料药、冻干粉针及其他剂型成品,用量从克级到公斤级,并提供 DMF 授权信。
下一代管线:从 BPA 到多个新型硼药和多种适应症
BPA 只是起点。我们的研发管线里,还有多个新型硼药项目:
?小分子(乳腺癌):已确定临床前候选化合物(PCC),细胞摄取是 BPA 的 2–3 倍,克隆形成抑制率约 90%,有望实现保乳治疗。正推进 IND 申报准备;
?小分子(骨肉瘤,罕见病):临床前阶段,满足美国/欧盟/日本孤儿药资格,T/N 比值达 18.4,有望实现保肢治疗
?小分子(胰腺癌):双代谢靶向,肿瘤富集度更高。预计 2027 年完成临床前研究。潜在价值:为胰腺癌患者提供胰腺切除手术之外的替代选择——胰腺切除是高度复杂的手术,对外科医生要求极高。
?小分子(前列腺癌):双代谢靶向,肿瘤富集度更高。预计 2027 年完成临床前研究。潜在价值:避免前列腺癌根治术及其高发的尿失禁风险。
?BDC 抗体-硼偶联物(乳腺癌、肺癌等):处于临床前研究阶段。1200 个硼原子/分子,靶向 HER2/HER1,为精准硼药开辟新方向。
共同目标:精准杀灭肿瘤,守护器官,为患者提供更好的生活质量。
硼药管线的价值,不仅在于"一台加速器配不同的药可以治不同的癌"——更在于:它能最大化设备利用率,让每一台加速器服务更多患者,满足未被满足的临床需求,让 BNCT 疗法从中国走向世界,惠及更多病人。
PART.06
普惠天下,利泽健康
普利制药的企业使命是:普惠天下 · 利泽健康。
这不仅是让中国患者用得上 BNCT疗法——更是希望这种疗法能走到世界更多地方。这也是为什么我们在申报美国 FDA、在与全球各地的医院和产业界对话。
BNCT 是一个需要共建的生态:设备方造枪,科学家研究子弹和机理,药企造子弹,医生和医院提供治疗手段,监管机构构建标准,投资方提供燃料。没有任何一方能独自把这件事做成。
在这个生态里,普利制药是那个把子弹造好的伙伴——从概念设计到PCC,从PCC到临床、注册、制造、全球化;药物线全链赋能。设备方造枪,我们造弹。
我们抱着开放的心态,愿意全方位合作——
?与设备方,探讨海外区域药械联合注册
?与医院,开展临床研究、课题申报
?如果你是药物科学家,我们可以合作,联合研究,把药物从论文转入现实。
?如果你是投资方,我们愿意携手做大产业共赢。
铸硼为刃,向瘤而行。
2028,中国见。
联系人:
周先生 zm@hnpoly.com
易女士 yirong@hnpoly.com
凌女士(HR)hnpolyhr@hnpoly.com
注:本文为行业信息,面向医疗和产业专业人士。文中涉及的硼药仍处于临床研究或临床前研究阶段,尚未在中国大陆获批上市,本文不构成任何用药或诊疗建议。是否适合某种治疗、能否参加临床研究,请与主治医生沟通。
免责及前瞻性声明(Disclaimer & Forward-Looking Statement)
本文仅作医药科普与企业信息介绍之用,内容整合公开披露资料及公司研发进展摘要,仅供参考。文中药品、项目相关表述不构成医疗诊疗建议、投资建议,亦不承诺未来相关成果;委托生产、原料药供应等合作安排需完成质量体系搭建与合规注册,最终以监管部门批复为准。本文所载数据、观点均基于文稿发布当日公开信息,公司不承担持续更新义务。
文中涉及注册申报、市场规划、业务发展等前瞻性陈述,均依托现有信息及合理假设作出,存在不确定性;受市场环境、行业政策等各类风险因素影响,实际情况或与预判存在较大差异,公司无义务因后续变动修订相关内容,敬请读者充分知悉风险、审慎判断。
Boron Neutron Capture Therapy: The New Cancer Treatment Segment, as China Takes the Baton for ICNCT 2028
October 30, 2026, Buenos Aires, Argentina.
At the closing ceremony of the 21st International Congress on Neutron Capture Therapy (ICNCT-21), a message traveled back from the Southern Hemisphere to China:
The next ICNCT will be held in China, in 2028.
Professor Chen Hesheng, Academician of the Chinese Academy of Sciences, will serve as the next Congress Chair.
1. What Is BNCT, and Why Does It Matter?
If this is your first time hearing about Boron Neutron Capture Therapy (BNCT), think of it as a form of "precision-targeted bombing" for cancer.
It works in two steps:
First, the patient receives an infusion of a boron-containing drug — e.g. boronophenylalanine (BPA). This drug has a remarkable property: it selectively accumulates in tumor cells, while healthy tissue takes up very little.
Second, the tumor is irradiated with a low-energy epithermal neutron beam. When a boron-10 nucleus captures a neutron, it undergoes fission, releasing two short-range particles (an alpha particle and a lithium-7 particle). These particles travel only about one cell diameter.
The higher the tumor-to-normal tissue (T/N) ratio — the boron concentration in tumor tissue versus normal tissue — the more the drug accumulates in the tumor and the less it lingers in healthy tissue. When the neutron beam is applied, the tumor receives far greater damage than surrounding healthy tissue, making treatment both safer and more effective. It is one of the core metrics for evaluating a boron drug's suitability for BNCT.
How is this different from conventional radiotherapy?
Conventional radiation therapy (X-rays, proton beams) is like "carpet bombing" — healthy tissue along the beam path is damaged along with the tumor. BNCT is like "precision-guided" — the drug finds the tumor on its own, and the neutron beam simply acts as the "detonator."
Its key advantages:
? Organ and function preservation: For adolescent osteosarcoma patients, BNCT means preserving limbs and preserving their ability to live independently. For breast cancer patients, it means preserving the breast and preserving dignity. For prostate cancer patients, it means avoiding radical prostatectomy and its high risk of urinary incontinence. This is not simply "cutting less" — it can reshape the trajectory of a person's entire life.
? A new hope for recurrent, end-stage patients: For patients who have exhausted multiple rounds of surgery, radiation, and chemotherapy, conventional treatment often offers no further options. BNCT is not limited by cumulative normal tissue dose — it is a beam of light in the darkness, the last line of defense when all other treatments have been tried.
? Short treatment course, lower equipment cost: Proton therapy typically requires about 30 treatment sessions, heavy-ion therapy about 12–16 sessions, while BNCT typically requires only 1–2 irradiations and can be completed on an outpatient basis. Compared with proton and heavy-ion systems, BNCT accelerators have lower capital investment and operating costs, making them easier to deploy across different countries.
Currently, BNCT is primarily used for locally recurrent head and neck cancers that are inoperable or ineligible for re-irradiation — because the therapy is new, approved indications currently cover locally recurrent, unresectable head and neck cancer, with expansion to other solid tumors expected.
2. What Happened at This Congress?
ICNCT is the oldest and most prestigious international academic conference in the BNCT field, held every two years since 1968. Over nearly six decades, the field has moved from the reactor era into the accelerator era, from a Japan-centered story to a globally distributed race. What new signals emerged at this congress?
Academia — latest progress across five frontiers:
1. Novel boron carriers and delivery systems: Beyond mature BPA, PBC-IP, albumin-conjugated boron molecules, BODIPY theranostic boron probes, and convection-enhanced delivery (CED, bypassing the blood-brain barrier) emerged as hot topics — addressing the challenge of insufficient BPA brain penetration in glioblastoma and other brain tumors.
2. Radiobiology and immune effects: BNCT-induced immunogenic cell death and extracellular vesicle markers continue to generate new data, providing a theoretical basis for combining BNCT with immunotherapy. Oral mucosal protection strategies are also being refined.
3. Dosimetry and bioequivalence conversion: There is still no globally unified standard for BNCT bioequivalent dose conversion across different radiation types and models; new concepts such as B-NIT continue to be discussed.
4. Clinical cohorts and indication expansion: Osaka presented long-term follow-up data on 285 head and neck cancer cases. Pediatric brain tumor and melanoma BNCT data were also published. Research on the correlation between glioblastoma surgical resection extent and BNCT prognosis provides further clinical evidence for BNCT as a post-surgical salvage treatment.
5. Boron imaging and in vivo boron quantification: Because 1?F-FBPA PET requires an on-site cyclotron due to fluorine-18's ~110-minute half-life, creating practical inconvenience for diagnosis and treatment, solid-state nuclear track detectors (SSNTD) and LA-ICP-MS quantification methods are advancing rapidly.
Industry — global device deployment is accelerating:
? Japan: The Kansai BNCT Medical Center has accumulated over 600 patient irradiations, with Osaka reporting 285 long-term follow-up cases — the world's deepest clinical dataset.
? Europe: Helsinki University Hospital in Finland launched Europe's first in-hospital accelerator-based BNCT clinical program in 2025, with Italy and Spain following.
? United States: The University of Wisconsin-Madison has entered the construction phase, and multiple accelerator companies have raised funding.
? South Korea: Accelerator-based BNCT projects are in progress.
? China: Multiple accelerator-based BNCT systems have entered clinical trials or regulatory review, with clinical exploration underway across hospitals in East and South China.A consensus is forming: BNCT is no longer "Japan's story" but a globally dispersed field — and China is moving from follower to the next center stage.
3.Why China?
The next congress is coming to China for a reason. Over the past few years, China has been catching up rapidly across the entire BNCT value chain — from accelerator equipment to boron drug development, from clinical deployment to academic output — not just following in one niche:
Guoke Neutron: Built on the China Spallation Neutron Source at the Institute of High Energy Physics (CAS) in Dongguan, Songshan Lake — described by CCTV as a "super microscope" for exploring the micro-world — China's first domestically developed accelerator-based BNCT system with full intellectual property rights is now operational, first installed at Dongguan People's Hospital. The system uses a 2.78 MeV radio-frequency quadrupole accelerator with a rotating lithium target, delivering an epithermal neutron flux of ≥1.02×10? n/s/cm2. In 2024, system availability exceeded 95%.
Poly Pharm: The BPA boron drug, developed in partnership with Guoke Neutron, is being used in clinical research led by Dr. Liu Zhigang's team at the Dongguan People's Hospital Oncology Center. Phase I completed 21 recurrent head and neck patients; Phase II is now underway.
HBNCT: Built around a "lithium target + BSA" compact accelerator paired with self-produced boronophenylalanine, forming a closed loop of "equipment + drug." Epithermal neutron flux of 1.2×10? n/cm2/s, proton energy 2.8 MeV, beam current ≥30 mA, treatment depth ≤11 cm, compliant with IEC 60601-2-93. Received NMPA clinical trial approval (IND) in March 2026, now entering Phase I.
Neuboron: First installed at Xiamen Humanity Hospital, having completed Phase I in recurrent head and neck cancer and initiated Phase II; system availability has exceeded 99% since November 2024. Self-developed NeuMANTA/COMPASS treatment planning system.
FDS (Fenglinhe): Built around the TopMC Monte Carlo engine, China's first dedicated neutron treatment planning system N-TPS, with dose engine deviation <3% (better than the IAEA's 7% recommendation) and AI-assisted planning completed within 10 seconds. Five bases across Chongqing, Qingdao, Nanjing, Anqing, and Hefei, covering the full spectrum of photon/electron, proton, and BNCT radiotherapy equipment.
Additionally, BNCT centers are under construction or already signed in Shandong, Zhejiang, Sichuan, and other provinces. The Hainan Boao Lecheng International Medical Tourism Pilot Zone has introduced a Japanese BNCT project. As of now, China has 4 centers in clinical trials, 3 in installation/commissioning, and 7 under construction or signed.
Beyond hardware, Chinese academic research is also advancing on multiple fronts. Nanjing University presented a physics-constrained machine learning algorithm for real-time online neutron spectrum reconstruction in accelerator-based BNCT. Professor Liu Zhibo's team at Peking University continues to publish on novel boron drug molecular design, with a dual-boron amino acid molecule featuring both PET imaging and BNCT therapeutic potential published in Angewandte Chemie. The Second Affiliated Hospital of Zhejiang University School of Medicine conducts systematic research on boron delivery agent development, microdosimetry, and treatment planning optimization. The Institute of Nuclear Science and Technology at Nanjing University of Aeronautics and Astronautics has long collaborated with Italy's INFN and the University of Pavia on key accelerator BNCT technologies, with results selected among Jiangsu Province's top ten international industry-academia cooperation achievements.
4. But Is a Device Enough?
No.
BNCT is a combination drug-device therapy — the neutron beam is the "gun," and the boron drug is the "bullet." Without the drug, even the most advanced accelerator is just an idling machine, unable to truly reach patients, unable to truly treat a single patient.
The boron drug determines three things:
1. How many patients can be treated: The higher the boron concentration in the tumor and the better the tumor-to-normal tissue (T/N) ratio, the larger the patient population that can benefit.
2. What cancers can be treated: Different boron drugs target different tumor types — BPA for head and neck cancer, novel boron drugs that can extend to breast cancer, osteosarcoma, pancreatic cancer, brain tumors.
3. Treatment accessibility: Whether the drug is locally approved, whether it can be supplied with stable GMP quality, and whether the price is affordable — these directly determine whether a device can truly serve patients.
The boundary that boron drugs can reach defines the clinical boundary of BNCT therapy.
Currently, only one BNCT drug is approved worldwide — borofalan (Steboronine) from Stella Pharma in Japan, available only domestically. Every new device entering clinical practice requires a locally approved, GMP-compliant boron drug supply.
This is why, as global BNCT device deployment accelerates, the boron drug side is becoming the most critical link in the entire industry chain.
5. What has Poly Pharm done in this field?
The first boron drug:
BPA — a fully integrated chain from raw material to clinical supply
1?B-BPA: Now in Phase II clinical trials. 99.9% chemical purity, 99% 1?B enrichment — from raw material to formulation to finished product, all produced in-house. The API has been filed with the US FDA as a Type II Drug Master File (DMF), and FDA pre-IND interactions have been completed. In China, Phase I clinical trials have been completed and Phase II is ongoing. We supply research-grade and GMP-grade API, lyophilized powder for injection, and other finished dosage forms, from gram to kilogram scale, with DMF authorization letters available.
Next-generation pipeline: from BPA to multiple novel boron drugs and multiple indications
BPA is only the starting point. Our R&D pipeline includes 5+ novel boron drug programs:
? Small molecule (Breast cancer): PCC confirmed; cellular uptake 2–3× that of BPA; ~90% clonogenic inhibition rate; potential for breast-conserving treatment. IND preparation underway.
? Small molecule (Osteosarcoma, orphan disease): Preclinical stage; meets orphan drug criteria in the US, EU, and Japan; T/N ratio of 18.4; potential for limb-sparing treatment.
? Small molecule (Pancreatic cancer): Dual metabolic targeting for higher tumor enrichment. Preclinical research expected to complete by 2027. Potential value: offering pancreatic cancer patients an alternative to pancreatic resection — a highly complex surgery that places extreme demands on surgical expertise.
? Small molecule (Prostate cancer): Dual metabolic targeting for higher tumor enrichment. Preclinical research expected to complete by 2027. Potential value: avoiding radical prostatectomy and its high risk of urinary incontinence.
? BDC Antibody-boron conjugate (Breast cancer, Lung cancer): Preclinical stage. 1,200 boron atoms per molecule, targeting HER2/HER1 — opening a new direction for precision boron drugs.
Shared goal: precisely destroy tumors, preserve organs, and improve quality of life for patients.
The value of a boron drug pipeline is not just "one accelerator, different drugs, different cancers" — it is about: maximizing device utilization so every accelerator serves more patients; meeting unmet clinical needs; and bringing BNCT therapy from China to the world, to benefit more patients.
6. Benefiting the World, Advancing Health
Poly Pharm's corporate mission is eight words: Benefiting the World, Advancing Health (普惠天下 · 利泽健康).
This is not just about making BNCT accessible to Chinese patients — it is about bringing this therapy to more places around the world. That is why we are filing with the US FDA and engaging with hospitals and industry partners globally.
BNCT is an ecosystem that must be built together: device makers build the gun, scientists research the bullets and mechanisms, drug companies build the bullets, doctors and hospitals provide the clinicaltreatment means, regulators establish standards, and investors provide the fuel. No single party can build this alone.
In this ecosystem, Poly Pharm is the partner that builds the bullets — from concept design to PCC, from PCC to clinical development, regulatory filing, manufacturing, and globalization; the full drug chain, fully enabled. Device makers build the gun; we supply the bullets.
With an open mind, we are ready for collaboration across the board:
? With device holders: explore overseas regional combined drug-device registration.
? With hospitals: conduct clinical research and joint grant applications.
? If you are a drug scientist: we welcome joint research to translate academic discovery into reality.
? If you are an investor: we invite you to join us in building this industry together.
Forging boron as a blade, advancing toward the tumor.
See you in China, 2028.
Contacts:
Mr. Zhou | zm@hnpoly.com
Ms. Yi | yirong@hnpoly.com
Ms. Ling (HR) | hnpolyhr@hnpoly.com
Disclaimer&Forward-Looking Statement:
This article provides industry information for medical and life sciences professionals. The boron drugs discussed are still in clinical or preclinical research stages and have not been approved for marketing in mainland of China. This article does not constitute any medical or treatment advice. Whether a treatment is suitable or whether a clinical trial can be joined should be discussed with the treating physician.
-END-
股票
板块
用户
资讯
评论 (0)